Sana Biotechnology Business Summary

Sana Biotechnology, Inc. (SANA) is a clinical-stage biotechnology company utilizing a business model centered on the development and future commercialization of engineered cell therapies, supplemented by strategic licensing and milestone-based R&D collaborations. The company operates through three primary therapeutic segments: oncology, type 1 diabetes (T1D), and B-cell mediated autoimmune diseases. Sana’s value proposition hinges on its proprietary Hypoimmune (HIP) platform, designed to create "off-the-shelf" allogeneic cells that evade immune rejection without the need for patient immunosuppression. This technological edge positions Sana as a high-potential disruptor in a market dominated by autologous treatments, competing directly with firms such as Allogene Therapeutics, Caribou Biosciences, and CRISPR Therapeutics. As of early 2026, the company has strategically pivoted to prioritize its T1D program (SC451) and in vivo CAR T delivery systems (SG293), leveraging a robust cash runway supported by recent equity financings and a 2022 partnership with Vertex Pharmaceuticals. The company was founded in 2018 by a high-pedigree "triumvirate" consisting of CEO Steve Harr, MD (former CFO of Juno Therapeutics and Managing Director at Morgan Stanley), Hans Bishop (former CEO of Juno Therapeutics and current Executive Chairman), and Richard Klausner, MD (former Director of the National Cancer Institute). The current executive leadership team includes Chief Technical Officer Snehal Patel, who brings deep manufacturing expertise from Genentech and Roche, and Chief Scientific Officer Dhavalkumar Patel, MD, PhD, formerly of UCB and Novartis. Sana’s board and cap table feature prominent industry figures and institutional backers, including ARCH Venture Partners, Flagship Pioneering, and F-Prime Capital, alongside notable individual investors such as Jeff Bezos (via Bezos Expeditions) and GV (Google Ventures). This leadership core combines extensive experience in cell therapy commercialization with a track record of multi-billion dollar exits, providing the strategic oversight necessary to navigate the complex regulatory landscape of genetic medicine.